Biotech Values

[genisi]

Biodel's formulation intended to provide faster onset of action than the currently available fast-acting insulin analogues. Nvo also thinks the need is there as you can tell from slide 12:

http://www.novonordisk.com/images/investors/investor_presentations/2011/CMD2011/04_Diabetes_treatment_tomorrow_CMD2011.pdf